TRX-103 is under development for the treatment of graft versus host disease (GvHD), Crohn’s disease and unspecified indication. The therapeutic candidate comprises of allogenic Treg-cells which are ...

Progesterone is under clinical development by Glia and currently in Phase III for Graft Versus Host Disease (GVHD).

New imaging technique able to identify early signs of graft-versus-host-disease in transplant patients. Read on!

The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that ...

Graft-versus-host disease (GvHD) is a complication of a bone marrow or stem cell transplant in which cells from a donor attack the tissues of the recipient. GvHD can be classified as being either ...

The allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy Ryoncil (remestemcel-L-rknd) has been approv ...

The FDA approves Mesoblast's Ryoncil (remestemcel-L) for treating pediatric patients with steroid-refractory acute graft ...

Investment risks and competition challenge Mesoblast Limited's recent approval for Remestemcel-L in treating ...

(Reuters) - The U.S. Food and Drug Administration on Wednesday approved Mesoblast's cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called ...

The therapy, branded as Ryoncil, is the first mesenchymal stromal cell therapy approved to treat pediatric patients aged two months and older whose GVHD symptoms have not responded to standard ...

MESO)'s cell therapy for treating a type of complication that occurs after a stem cell or bone marrow transplant called graft-versus-host disease (GVHD). The therapy, branded as Ryoncil ...

Mesoblast stock climbs 80% in a month following the FDA's approval of Ryoncil as the only approved therapy for SR-aGVHD in children aged two months and older.